Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Avalo Therapeutics (AVTX) Shares Outstanding (2016 - 2025)

Avalo Therapeutics' Shares Outstanding history spans 12 years, with the latest figure at $18.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 76.78% year-over-year to $18.5 million; the TTM value through Dec 2025 reached $18.5 million, up 76.78%, while the annual FY2025 figure was $18.5 million, 76.78% up from the prior year.
  • Shares Outstanding reached $18.5 million in Q4 2025 per AVTX's latest filing, up from $17.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $18.5 million in Q4 2025 to a low of $39164.0 in Q4 2021.
  • Average Shares Outstanding over 5 years is $6.6 million, with a median of $8.0 million recorded in 2021.
  • The largest YoY upside for Shares Outstanding was 1940.38% in 2023 against a maximum downside of 99.41% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $39164.0 in 2021, then increased by 0.33% to $39294.0 in 2022, then skyrocketed by 1940.38% to $801746.0 in 2023, then surged by 1206.14% to $10.5 million in 2024, then soared by 76.78% to $18.5 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Shares Outstanding are $18.5 million (Q4 2025), $17.8 million (Q3 2025), and $10.8 million (Q2 2025).